FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed is application of 2-(2-nitro-4-trifluormethylbenzoyl)-1,3-cyclohexandione in production of medication in treatment of neurodegenerative disease, Parkinson's disease, as well as pharmaceutical compositions and sets (versions) of similar purpose, which include said compound.
EFFECT: compound inhibits 4-hydroxypyruvate dioxygenase, reduces time of recovery from catalepsy and increases availability of levodopa or increases dopamine synthesis, i.e. ensures action synergism in treatment of neurodegenerative disease, Parkinson's disease.
23 cl, 4 dwg, 7 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT-MEDIATED DISORDERS | 2015 |
|
RU2707749C2 |
| COMPOSITIONS, BASED ON 2-AMINO-1,3-RPOPANEDIOL COMPOUNDS | 2010 |
|
RU2468793C2 |
| NEW OPTIONS OF USE OF PIPERIDINYLINDOLE DERIVATIVES | 2018 |
|
RU2787991C2 |
| COURSE OF TREATMENT WITH APPLICATION OF RECEPTOR S1P AGONIST | 2005 |
|
RU2478384C2 |
| SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | 2011 |
|
RU2603637C2 |
| BRIDGED N-CYCLYC SULPHONAMIDO-INHIBITORS OF GAMMA-SECRETASE | 2006 |
|
RU2422443C2 |
| NMDA RECEPTOR MODULATORS AND USING THEM | 2009 |
|
RU2515615C2 |
| COMBINATIONS CONTAINING mGluR MODULATORS FOR TREATING PARKINSON'S DISEASE | 2009 |
|
RU2496494C2 |
| 2-AMINOPYRIDINE OR 2-AMINOPYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | 2019 |
|
RU2790006C2 |
| β-LACTAMYL-SUBSTITUTED ANALOGUES OF PHENYLALANINE, CYSTEINE AND SERINE AS VASOPRESSIN ANTAGONISTS | 2006 |
|
RU2466991C2 |
